查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046360

人工智慧在精準醫療領域的市場－全球產業規模、佔有率、趨勢、機會和預測：按技術、組件、治療應用、地區和競爭格局分類，2021-2031年

Artificial Intelligence In Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Component, By Therapeutic Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球精準醫療人工智慧 (AI) 市場預計將大幅擴張，從 2025 年的 17.8 億美元成長到 2031 年的 31.2 億美元，複合年成長率高達 9.81%。

這一成長歸功於機器學習和深度學習等先進計算演算法在分析複雜生物學和臨床數據方面的應用。這些應用能夠根據每位患者獨特的基因組成、生活方式和環境因素，精準地客製化醫療介入、決策和治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 17.8億美元
市場規模：2031年 31.2億美元
複合年成長率：2026-2031年 9.81%
成長最快的細分市場 硬體
最大的市場 北美洲

推動市場發展的關鍵因素包括大規模基因組數據的快速成長、降低高昂藥物研發成本的迫切經濟需求，以及需要標靶治療的慢性疾病在全球範圍內的發病率不斷上升。例如，美國醫學會 (AMA) 在 2025 年發布的報告中指出，到 2024 年，將有 66% 的醫生在醫療保健領域使用人工智慧 (AI)，這表明人工智慧的應用將顯著成長。然而，儘管市場發展勢頭良好，但仍面臨著許多挑戰，尤其是在資料隱私和安全方面。處理高度敏感的患者資訊需要克服複雜的監管障礙，這可能會阻礙市場進一步滲透。

市場促進因素

推動精準醫療領域採用人工智慧的主要動力源自於醫療服務體系迫切需要降低成本並提高效率。面對日益成長的財務壓力，醫療機構正擴大採用人工智慧解決方案來自動化行政任務並最佳化資源分配。這些技術不僅簡化了操作流程，使醫護人員更專注於患者照護，還能大幅降低成本。正如英偉達 (NVIDIA) 2025 年 3 月發布的報告《人工智慧在醫療保健和生命科學領域的現狀》所示，73% 的機構認為降低營運成本是採用人工智慧的主要益處，而這種效率提升也延伸到了臨床操作領域，例如檢驗診斷結果和更有效地對患者風險進行分層。

此外，藥物發現和開發週期的加速正在從根本上改變精準醫療的格局，解決傳統藥物研發中固有的效率低下問題。傳統方法通常需要10年以上才能將新治療方法推向市場，而人工智慧驅動的平台可以快速識別有前景的藥物靶點，並設計出成功率極高的新型分子。例如， In Silico Medicine於2025年2月發布的《臨床前藥物發現基準》報告指出，臨床前候選化合物的平均篩選時間僅為13個月，相比傳統的2.5至4年流程有了顯著提升。這些技術進步也得到了實際應用的支持。Astra Zeneca於2025年3月在歐洲肺癌研究協會會議上發表的研究表明，人工智慧驅動的胸部X光診斷工具的陽性預測率達到了54.1%，凸顯了人工智慧在提高診斷準確性和臨床試驗篩檢效率方面的能力。

市場挑戰

人工智慧在全球精準醫療市場發展面臨的主要障礙之一是資料隱私和安全的複雜挑戰。精準醫療本質上依賴整合龐大且多樣化的資料集，包括基因組序列、電子健康記錄和即時病患監測數據，以有效地訓練複雜的人工智慧演算法。然而，由於這些資訊高度敏感，必須遵守嚴格的法規結構，導致資料孤島現象普遍存在。這些孤島使得各機構難以合法地共用檢驗不同人群人工智慧模型所必需的多樣化資料集，從而阻礙了通用演算法的開發，並限制了獲取最大限度減少偏差和確保臨床準確性所需的廣泛數據。

網路攻擊威脅日益加劇，令這些挑戰雪上加霜，導致許多醫療機構在採用基於雲端的人工智慧解決方案時猶豫不決。根據醫療資訊管理系統協會 (HIMSS) 2025 年的一項調查，高達 75% 的醫療網路安全專業人員表示，資料隱私是他們未來在醫療環境中整合人工智慧時最主要的擔憂。這種普遍的擔憂迫使醫療機構優先考慮防禦性安全措施，而非創新性的人工智慧整合，導致關鍵投資被轉移。因此，對資料外洩及其潛在法律後果的擔憂，透過增加營運成本和延長新技術商業部署所需的時間，直接限制了市場成長。

市場趨勢

人工智慧在精準醫療領域的市場格局正受到人工智慧驅動的放射組學和計算病理學日益普及的影響，這些技術正在從根本上改變診斷流程。這些先進技術能夠對複雜的組織特徵定量評估，而這些特徵在主觀的人工評估中往往被忽略。透過整合深度學習演算法，對數位化組織樣本和醫學影像進行精細分析，這些工具能夠標準化生物標記的定量分析，並提高標靶治療患者分層的準確性。這種方法能夠揭示腫瘤微環境中細微且通常難以察覺的模式，從而減少觀察者間的差異，並有助於做出更精準的治療決策。例如，Proscia 於 2025 年 6 月發表的題為「2025 年 ASCO 大會上數位病理學和人工智慧的亮點」的文章詳細介紹了一項多中心研究，該研究表明，人工智慧驅動的分析將病理學家在 HER2 低表達乳癌評分方面的診斷一致性提高到 86.4%，與傳統的人工評估方法相比，這是一個顯著的進步一致性。

同時，生物製藥公司與科技公司之間策略合作的激增以及強大生態系統的形成，正在加速市場成長。製藥公司擴大與專業的AI公司合作，以確保獲得廣泛的真實世界數據和專有運算平台。這些策略合作簡化了縱向臨床資料集和基因組資訊的整合，從而建立了一個強大的生態系統，加速了藥物發現和精準醫療的假設檢驗。生物製藥行業的領導者正在利用這些外部技術堆疊，而不是從零開始建立內部能力，以高效應對多體學數據的複雜性和監管合規性問題。 Tempus AI於2026年1月發布的「2025會計年度中期業績」印證了這一趨勢，該業績顯示契約總價值超過11億美元，並簽署了70多份數據契約，凸顯了這些合作數據生態系統的快速商業性價值以及企業運營對其的高度依賴。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：人工智慧在精準醫療領域的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過科技（深度學習、查詢方法、自然語言處理、情境辨識處理）
    • 按組件（硬體、軟體、服務）
    • 按領域分類的治療（腫瘤科、循環系統、神經科、呼吸內科等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美精準醫療人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲精準醫療人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區精準醫療人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲精準醫療人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：人工智慧在南美洲精準醫療領域的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球精準醫療人工智慧市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Glanbia Plc
  • BioXcel Therapeutics, Inc.
  • Sanofi SA
  • NVIDIA Corp.
  • Alphabet Inc.
  • IBM Technology corporation
  • Microsoft Corporation
  • Intel Corp.
  • AstraZeneca plc
  • GE HealthCare Technologies Inc.
  • Enlitic, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16237

The Global Artificial Intelligence in Precision Medicine Market is poised for significant expansion, projected to grow from USD 1.78 Billion in 2025 to USD 3.12 Billion by 2031, demonstrating a robust 9.81% Compound Annual Growth Rate. This growth is driven by the application of advanced computational algorithms, notably machine learning and deep learning, to analyze complex biological and clinical data. Such applications enable the precise customization of healthcare interventions, medical decisions, and treatments, tailoring them to each patient's unique genetic makeup, lifestyle, and environmental factors.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.78 Billion
Market Size 2031USD 3.12 Billion
CAGR 2026-20319.81%
Fastest Growing SegmentHardware
Largest MarketNorth America

Key market drivers include the rapid proliferation of large-scale genomic data, the urgent economic need to curtail high drug discovery costs, and the rising global incidence of chronic diseases demanding targeted therapies. For example, the American Medical Association reported in 2025 that 66% of physicians were utilizing healthcare artificial intelligence in 2024, marking a substantial increase in adoption. However, despite this positive momentum, the market faces considerable challenges, particularly concerning data privacy and security, as the handling of sensitive patient information necessitates navigating complex regulatory hurdles that could impede broader market penetration.

Market Driver

A primary force propelling the adoption of artificial intelligence in precision medicine is the urgent need for cost containment and enhanced efficiency within healthcare delivery systems. Faced with escalating financial pressures, healthcare organizations are increasingly implementing AI solutions to automate administrative tasks and optimize resource allocation. These technologies not Monly streamline operations, allowing providers to concentrate more on patient care, but also significantly reduce expenditures. As evidenced by NVIDIA's March 2025 "State of AI in Healthcare and Life Sciences" report, 73% of organizations identified reductions in operating costs as a key benefit of AI integration, with this efficiency extending to clinical settings for tasks such as validating diagnostic results and more effectively stratifying patient risks.

Furthermore, the acceleration of drug discovery and development timelines is fundamentally reshaping the precision medicine landscape by addressing the inherent inefficiencies of traditional pharmaceutical research and development. While conventional methods often require over a decade to bring a new therapy to market, AI-driven platforms can swiftly identify viable drug targets and design novel molecules with a higher probability of success. Insilico Medicine's February 2025 "Preclinical Drug Discovery Benchmarks" announcement, for instance, highlighted their average 13-month timeline to nominate preclinical candidates, a substantial improvement over the traditional 2.5 to 4-year process. Real-world applications further validate these technological advancements, with AstraZeneca's March 2025 findings at the European Lung Cancer Congress showcasing an AI-powered chest X-ray tool that achieved a 54.1% positive predictive value, underscoring AI's capacity to enhance diagnostic precision and clinical trial screening efficiency.

Market Challenge

A significant impediment to the growth of the Global Artificial Intelligence in Precision Medicine Market is the intricate challenge surrounding data privacy and security. Precision medicine inherently relies on aggregating vast, diverse datasets-including genomic sequences, electronic health records, and real-time patient monitoring data-to effectively train complex AI algorithms. Yet, the extremely sensitive nature of this information mandates strict adherence to rigorous regulatory frameworks, which frequently result in data silos. These silos make it difficult for organizations to legally share the varied datasets essential for validating AI models across different demographic groups, thereby hindering the development of universally applicable algorithms and limiting access to the broad data spectrum needed to minimize bias and ensure clinical accuracy.

The escalating threat of cyberattacks further compounds these difficulties, leading many healthcare providers to hesitate in adopting cloud-based AI solutions. According to the Healthcare Information and Management Systems Society in 2025, a notable 75% of healthcare cybersecurity professionals identified data privacy as a paramount concern regarding the future integration of artificial intelligence in healthcare settings. This widespread apprehension compels institutions to prioritize defensive security measures over innovative AI integration, effectively diverting crucial investment. Consequently, the apprehension surrounding data breaches and their potential legal ramifications directly constrains the market's trajectory by increasing operational costs and extending the timelines required for the commercial deployment of new technologies.

Market Trends

The market for AI in precision medicine is significantly shaped by the expanding adoption of AI-driven radiomics and computational pathology, which are fundamentally transforming diagnostic workflows. These advanced technologies enable the quantitative assessment of complex tissue characteristics that are often imperceptible through subjective human review. By deploying deep learning algorithms to meticulously analyze digitized histological slides and medical images, these tools standardize biomarker quantification and enhance the precision of patient stratification for targeted therapies. This approach uncovers subtle, sub-visual patterns within the tumor microenvironment, thereby reducing inter-observer variability and facilitating more accurate treatment decisions. Proscia's June 2025 "Digital Pathology and AI Highlights from ASCO 2025" report, for instance, detailed a multi-center study where AI-assisted analysis boosted diagnostic agreement among pathologists to 86.4% for HER2-low breast cancer scoring, marking a substantial improvement over traditional manual assessment methods.

Concurrently, a surge in strategic biopharma-tech partnerships and the formation of robust ecosystems are accelerating market growth. Pharmaceutical companies are increasingly collaborating with specialized AI firms to gain access to extensive real-world data and proprietary computational platforms. These strategic alliances streamline the integration of longitudinal clinical datasets with genomic information, fostering resilient ecosystems that both expedite drug discovery and validate precision medicine hypotheses. Rather than building internal capabilities from the ground up, biopharma leaders are leveraging these external technology stacks to efficiently navigate the complexities of multi-omics data and regulatory compliance. Evidence of this trend is seen in Tempus AI's January 2026 "Preliminary 2025 Financial Results" announcement, which reported a total contract value exceeding $1.1 billion and the establishment of over 70 data agreements, underscoring the rapid commercial validation and operational reliance on these collaborative data ecosystems.

Key Market Players

  • Glanbia Plc
  • BioXcel Therapeutics, Inc.
  • Sanofi S.A.
  • NVIDIA Corp.
  • Alphabet Inc.
  • IBM Technology corporation
  • Microsoft Corporation
  • Intel Corp.
  • AstraZeneca plc
  • GE HealthCare Technologies Inc.
  • Enlitic, Inc.

Report Scope

In this report, the Global Artificial Intelligence In Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Precision Medicine Market, By Technology

  • Deep Learning
  • Querying Method
  • Natural Language Processing
  • Context-Aware Processing

Artificial Intelligence In Precision Medicine Market, By Component

  • Hardware
  • Software
  • Service

Artificial Intelligence In Precision Medicine Market, By Therapeutic Application

  • Oncology
  • Cardiology
  • Neurology
  • Respiratory
  • Other

Artificial Intelligence In Precision Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Precision Medicine Market.

Available Customizations:

Global Artificial Intelligence In Precision Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Intelligence In Precision Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Deep Learning, Querying Method, Natural Language Processing, Context-Aware Processing)
    • 5.2.2. By Component (Hardware, Software, Service)
    • 5.2.3. By Therapeutic Application (Oncology, Cardiology, Neurology, Respiratory, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Artificial Intelligence In Precision Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Component
    • 6.2.3. By Therapeutic Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Artificial Intelligence In Precision Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Component
        • 6.3.1.2.3. By Therapeutic Application
    • 6.3.2. Canada Artificial Intelligence In Precision Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Component
        • 6.3.2.2.3. By Therapeutic Application
    • 6.3.3. Mexico Artificial Intelligence In Precision Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Component
        • 6.3.3.2.3. By Therapeutic Application

7. Europe Artificial Intelligence In Precision Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Component
    • 7.2.3. By Therapeutic Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Artificial Intelligence In Precision Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Component
        • 7.3.1.2.3. By Therapeutic Application
    • 7.3.2. France Artificial Intelligence In Precision Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Component
        • 7.3.2.2.3. By Therapeutic Application
    • 7.3.3. United Kingdom Artificial Intelligence In Precision Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Component
        • 7.3.3.2.3. By Therapeutic Application
    • 7.3.4. Italy Artificial Intelligence In Precision Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Component
        • 7.3.4.2.3. By Therapeutic Application
    • 7.3.5. Spain Artificial Intelligence In Precision Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Component
        • 7.3.5.2.3. By Therapeutic Application

8. Asia Pacific Artificial Intelligence In Precision Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Component
    • 8.2.3. By Therapeutic Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Artificial Intelligence In Precision Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Component
        • 8.3.1.2.3. By Therapeutic Application
    • 8.3.2. India Artificial Intelligence In Precision Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Component
        • 8.3.2.2.3. By Therapeutic Application
    • 8.3.3. Japan Artificial Intelligence In Precision Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Component
        • 8.3.3.2.3. By Therapeutic Application
    • 8.3.4. South Korea Artificial Intelligence In Precision Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Component
        • 8.3.4.2.3. By Therapeutic Application
    • 8.3.5. Australia Artificial Intelligence In Precision Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Component
        • 8.3.5.2.3. By Therapeutic Application

9. Middle East & Africa Artificial Intelligence In Precision Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Component
    • 9.2.3. By Therapeutic Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Artificial Intelligence In Precision Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Component
        • 9.3.1.2.3. By Therapeutic Application
    • 9.3.2. UAE Artificial Intelligence In Precision Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Component
        • 9.3.2.2.3. By Therapeutic Application
    • 9.3.3. South Africa Artificial Intelligence In Precision Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Component
        • 9.3.3.2.3. By Therapeutic Application

10. South America Artificial Intelligence In Precision Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Component
    • 10.2.3. By Therapeutic Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Artificial Intelligence In Precision Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Component
        • 10.3.1.2.3. By Therapeutic Application
    • 10.3.2. Colombia Artificial Intelligence In Precision Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Component
        • 10.3.2.2.3. By Therapeutic Application
    • 10.3.3. Argentina Artificial Intelligence In Precision Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Component
        • 10.3.3.2.3. By Therapeutic Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Artificial Intelligence In Precision Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Glanbia Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BioXcel Therapeutics, Inc.
  • 15.3. Sanofi S.A.
  • 15.4. NVIDIA Corp.
  • 15.5. Alphabet Inc.
  • 15.6. IBM Technology corporation
  • 15.7. Microsoft Corporation
  • 15.8. Intel Corp.
  • 15.9. AstraZeneca plc
  • 15.10. GE HealthCare Technologies Inc.
  • 15.11. Enlitic, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer